LEGN250117P65000
- 0.00
- 0.000.00%
Legend Biotech Newsroom
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Legend Biotech Analyst Ratings
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
Legend Biotech: Strong Buy Rating Driven by Competitive Positioning of CARVYKTI Amidst Safety and Regulatory Confidence
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $84
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Promising Growth Trajectory and Market Expansion Justify Buy Rating for Legend Biotech
RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating
Legend Biotech Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and NewAmsterdam Pharma Company (NAMS)
Piper Sandler Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $78
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $65 to $91
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Optimistic Buy Rating for Legend Biotech Driven by Carvykti's Success and Growth Potential
William Blair Sticks to Its Hold Rating for Legend Biotech (LEGN)
Legend Biotech Analyst Ratings